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Effects of high‑intensity training 
on the quality of life of cancer 
patients and survivors: a systematic 
review with meta‑analysis
Ana Myriam Lavín‑Pérez1,2,3, Daniel Collado‑Mateo2*, Xián Mayo2, Gary Liguori4, 
Liam Humphreys5, Robert James Copeland5 & Alfonso Jiménez2,3,5
Cancer and associated medical treatments affect patients’ health‑related quality of life (HRQoL) 
by decreasing functional dimensions of physical, social, cognitive, and emotional well‑being, while 
increasing short and late‑term symptoms. Exercise, however, is demonstrated to be a useful therapy 
to improve cancer patients’ and survivors’ HRQoL, yet the effectiveness of high‑intensity training 
(HIT) exercise is uncertain. This systematic review and meta‑analysis aimed to analyse the effects of 
HIT on HRQoL dimensions in cancer patients and survivors as well as evaluate the optimal prescription 
of HIT. The search followed the Preferred Reporting Items for Systematic Reviews and Meta‑Analyses 
guidelines (PRISMA) and examined Web of Science and PubMed (Medline) databases. Data were 
analysed utilizing Review Manager Software. Twenty‑two articles were included in the systematic 
review and 17 in the meta‑analysis. Results showed HIT improved global quality of life, physical 
functioning, role functioning, social functioning, cognitive functioning, fatigue, pain, dyspnea, and 
insomnia, compared to an inactive control group, yet no differences were found between HIT and 
low to moderate‑intensity exercise interventions. Particular improvements in HRQoL were observed 
during cancer treatment and with a training duration of more than eight weeks, a frequency of 2 days/
week, and a volume of at least 120 min/week, including 15 min or more of HIT. Our findings whilst 
encouraging, highlight the infancy of the extant evidence base for the role of HIT in the HRQoL of 
cancer patients and survivors.
Cancer survivorship continues to increase, with the latest data indicating an estimated 16.9 million people have 
survived cancer in the United States. This figure is projected to reach more than 26 million by  20401. Moreover, 
by 2040, 73% of cancer survivors will be at least 65 years old, suggesting a higher comorbidity  burden1. Cancer 
and associated therapies can have severe consequences, including treatment-related side effects that decrease 
health-related quality of life (HRQoL). HRQoL represents the perception of an individual’s current physical, 
social, emotional, and cognitive health (functional dimensions), together with individual wellbeing and the 
cancer symptoms  suffered2. HRQoL is an important variable to consider when making clinical  decisions2, and 
HRQoL correlates with patients’ cardiorespiratory  fitness3 and cancer-specific  mortality4 in different types of 
cancer such as  breast5–7,  lung8,  colon9,  prostate10.
Short- and long-term11 effects of cancer treatments have been shown to compromise patients’ HRQoL. Short-
term effects include symptoms of  fatigue12, weight  loss13, weight  gain14, sarcopenia and  cachexia15, nausea/vomit-
ing16,  pain17, hair  loss18,  dyspnea19, insomnia (sleep disturbance)20,  constipation21, and  drowsiness22. Symptoms 
such as diarrhea, appetite loss, sore mouth, and sweating are also  reported23. Late effects of chemotherapy and 
radiation therapy most commonly include secondary  cancers24 and cardiovascular  disease25. Short-term and 
late effects vary depending on a patients’ medical history and treatment  exposures11, and can directly impact a 
survivors physical and mental health, which can worsen with the increased comorbidities that likely occur with 
 aging26. Thus, cancer patients’ HRQoL functional capacities, which include physical, emotional, cognitive, social, 
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and mental components, may be negatively affected during and after treatment, and this negative experience 
may last throughout  survivorship27.
In addition to pharmacological therapies, numerous interventions (e.g. psychological therapies, meditation, 
alternative medicines) are available that aim to reduce the effects of cancer, including treatment-related side 
effects of cancer  drugs28. The role of exercise as a cancer therapy appears promising given its potential impact on 
variables such as physical and mental health, cancer symptoms, and clinical  components29. Exercise programs 
are known to help improve the management of treatment side-effects, improve functional  outcomes30, enhance 
global quality of life, and help manage  fatigue31. Several meta-analyses and systematic reviews have investigated 
the role of exercise in the HRQoL of cancer survivors, trying to approximate the best dose–response and the 
critical exercise loading characteristics of frequency, intensity, type (FITT). Sweegers et al. (2018) and Buffat 
et al. (2017) concluded that supervised exercise programmes can improve HRQoL and physical  function32,33 and 
are more beneficial than unsupervised interventions. Furthermore, in Hong et al. (2019) meta-analysis, positive 
social functioning effects were found as a result of exercise, with the largest benefits seen when exercise sessions 
were 45 to 90 min in  duration34. Moreover, physical cancer symptoms of fatigue, pain, insomnia, and dyspnoea 
also showed a decrease with exercise  programmes35.
Low-intensity exercise has been shown to improve depression, anxiety, and overall physical  functioning36. 
Moderate-to-vigorous exercise has demonstrated improvements in physical function and reductions in cancer-
related  consequences30. High Intensity Training (HIT) has yielded positive  effects37 on cardiorespiratory  fitness38, 
 strength39, and body  composition40, as well as reduced tumor  growth41. Although the use of HIT as part of cancer-
related therapy is increasing, its benefits on HRQoL are unclear. Toohey et al. (2017) systematically reported a 
higher effect on HRQoL in patients using HIT. Whereas Mugele et al. (2019) stated that HIT did not improve 
global health status, pain, fatigue, or insomnia. Adams’ et al. (2018) found improvements in cancer-related fatigue 
and self-esteem when assessed by the Functional Assessment of Cancer Therapy-Fatigue questionnaire. These 
reviews point out the need for further investigation to clarify the possible beneficial effects of HIT in cancer 
patients and survivors. Therefore, the primary aim of this study was to explore the effect of HIT on HRQoL 
dimensions in cancer patients and survivors. Second, we aimed to evaluate the characteristics of HIT for each 
HRQoL dimension with regard to the intervention timing related to the cancer treatment, mode of exercise, and 
dose (i.e. duration and frequency).
Methods
The methodology of the current systematic review was carried out according to the PRISMA (Preferred Report-
ing Items for Systematic reviews and Meta-Analyses)  guidelines42. The systematic review was registered with the 
International Prospective Register of systematic reviews (PROSPERO), identification number CRD42020167203. 
In this manuscript, we reported the effects on each HRQoL dimension, which includes more than 100 meta-
analyses that have been summarized in tables and in the supplementary data. For readers interested in the effects 
of HIT on cardiorespiratory fitness outcomes in cancer, these have been reported  elsewhere43.
Data sources and searches. PubMed (MEDLINE) and Web of Sciences (which includes articles indexed 
in the KCI-Korean Journal Database, MEDLINE, Russian Science Citation Index, and SciELO Citation Index) 
databases were used for article searches. The boolean operators employed were (cancer or “neoplasm”) and 
(HIIT or “high intensity”) and (“quality of life” or “hrqol” or “qol”), limiting the results to articles published in 
the last 10 years and written in English or Spanish. The search was done from November 2019 to March 2020. 
The search for published studies was independently performed by two authors (A.M.L-P and D.C-M.), and disa-
greements were resolved through discussion.
The inclusion criteria established to select the articles were: (a) studies involving any kind of cancer patients, 
(b) interventions with any kind of high-intensity exercise, (c) articles with any HRQoL outcome registered, and 
(d) investigations including at least one other group to compare the effects of HIT. Additionally, interventions 
were excluded in cases of being a letter to the editor, a consensus or guideline, a study protocol or study design, a 
case report, a follow-up study, meta-analysis, or systematic review. The current review considered high-intensity 
training as any program (cardiovascular and/or resistance exercise) whose authors classified it as “high-intensity”, 
including both high intensity interval training and high intensity training.
Risk of bias assessment. The analysis of the risk of bias was done using the PEDro scale. The scale is 
known as a valid and reliable instrument to assess eligibility, allocation to groups, blinding of allocation, and 
comparison between groups at baseline and its  outcomes44. The leading reason for its selection is due to it being 
the most used in the Sport Sciences for Health scientific  area45.
Data extraction. The main data of participants, intervention, comparisons, results, and study design 
(PICOS) of each group included in the articles were reported according to the PRISMA  methodology42. Regard-
ing participants, studies sample size, patients age (mean and standard deviation) and body mass index (BMI), 
type of cancer, stage, cancer treatment, and exercise intervention timing concerning the therapy phase were 
reported. The intervention characteristics registered were: program length (in weeks), duration of sessions, 
weekly frequency, a description of the exercise, its corresponding intensity (control and progression), and adher-
ence data. HRQoL was the outcome reported in this review. The questionnaires used in the different studies were 
the European Organisation for Research and Treatment of Cancer quality of life Questionnaire C30 (EORTC 
QLQ-C30), the Functional Assessment of Cancer Therapy (FACT), and the Short-form 36 (SF-36). Results 
regarding the questionnaires used are in the meta-analysis figures or the supplementary data tables. Of all the 
surveys, the EORTC QLQ-C30 questionnaire was the most commonly reported and the one with more specific 
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variables  analyzed46. To make a representative analysis, the EORTC QLQ-C30 dimensions were used to group 
FACT and SF-36 results. We examined all the questionnaire’s dimensions and related items to establish similari-
ties between the categories. We did this even if there were named differences, but their items evaluated the same 
topic. Item categorization was analyzed by two of the researchers (AMLP and DCM) who discussed similarities 
and differences to classify them in useful variables for the meta-analysis. The variables were divided into catego-
ries consistent with EORTC QLQ.C30 dimensions, distinguishing global health, functional scale, and symptoms 
scale. The data from those items that did not correspond to any variable group created, or was registered by less 
than three articles, was not included in the literature part.
Statistical analysis. Post-intervention means and standard deviations were extracted from the articles and 
analyzed using Review Manager Software (RevMan, 5.3)47 based on; High-intensity exercise group (HIEG), 
low-to-moderate exercise group (LMEG), and inactive control group (CG). When outcomes were evaluated on 
scales with opposite directions, (e.g. pain or fatigue), one of the results directions was multiplied by −  148. The 
results were reported using standardized mean differences (SMDs) and interpreted according to the Cochrane 
 Handbook48 i.e. small effects with scores < 0.4, moderate effects from 0.4 to 0.7, and large effects with > 0.7. The 
statistical method employed was inverse variance with random  effects49 and the interval confidence (CI) utilized 
was 95%.
Different analyses were computed for each dimension (Global health, Physical functioning, Role function-
ing/physical role, Emotional functioning/wellbeing and mental health, Cognitive functioning, Social function-
ing, Fatigue/vitality, Nausea, Body pain, Dyspnoea, Constipation, Insomnia, Diarrhoea and Appetite loss). The 
described procedure was carried out, first, to analyze the difference according to the type of intervention group: 
LMEG or CG. Secondary calculations were performed contrasting HIEG and CG outcomes with more detail 
making the following subgroups analysis: (1) interventions conducted before, during, or after cancer treatment, 
(2) interventions of ≤ 8 weeks or > 8 weeks, (3) only aerobic exercise programs or work-outs with any resistance 
component, (4) studies where participants exercised ≤ 2 times per week or those > 3 times per week (5) interven-
tions of ≤ 120 min or > 120 min per week, (6) training designs with a high-intensity aerobic session part of 15 min 
or less and separately those with greater than 15 min duration.
Results
Study selection. Figure 1 sets out the data from the study selection process. The search obtained 385 arti-
cles, 157 in the PubMed database and 228 in Web of Science. Two more papers were identified in the references 
of articles and were therefore  included50,51. One hundred thirty-five of the found studies were duplicated, so 251 
were screened by examining the title and abstract. Following the exclusion criteria, one animal intervention, 
Figure 1.  Study flow diagram.
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seven conference abstracts, 69 reviews, three consensus or guideline writings, 15 studies not focused on cancers, 
62 not involving a high-intensity intervention, six case reports, and 32 study designs were removed. Fifty-six 
articles were full-text analyzed. From those, 16 were excluded because they did not have HRQoL as a variable, 
seven did not include a CG, eight did not carry out a HIT programme (most of them were respiratory exercises), 
and three were follow-up studies. In total, 22 studies were eligible for the systematic review, and from those six-
teen had data to be included in the meta-analysis process.
Risk of bias. The risk of bias was evaluated using the PEDro scale and ranged from 3 to 8, see Table 1 (being 
10 the best score of the scale). The mean of the scores was 6.3. All the articles fulfilled Items 1 (“the election 
criteria were specified”) and 10 (“the results of between-group statistical comparisons are reported for at least 
one key outcome”). Item 5 “there was blinding of all subjects” and 6 “there was blinding of all therapists who 
administered the therapy” were only reaches by two of the includes  studies52.
Characteristics of the participants. Table 2 shows the meta-analysis participants’ baseline character-
istics. The information from the articles included in the systematic review but not in the meta-analysis are 
presented in Supplementary Table S1 and Table S2. The global sample size of the systematic review was 2457, 
composed of 1080 participants of HIEG, 385 which participated in LMEG, and 992 from inactive CG and. 
Participants aged ranged from 27.8 to 72 with a mean of 51.56 in HIEG, 53.35 years in LMEG, and 51.6 in CG 
Patients’ mean BMI ranged from 22.6 to 31 kg/m2 and often were not regularly physically active.
The selected articles involved different types of cancer. Some papers specified the intervention in one type of 
cancer, such as breast  cancer39,51,53–57 (being the most common in the studies included), colon  cancer51,58,59, lung 
 cancer60–62 prostate  cancer54, testicles  cancer63 or rectal  cancer50. Other authors designed programmes mixing 
participants with different kinds of  cancer37,57,64–69. Moreover, the exercise interventions found could be distin-
guished by the timing within the cancer pathway:  before59,  during50,51,53,56–58,60,61,68–71 or after  treatment54,62,65,66,72,73.
Characteristics of the exercise programs. The intervention descriptions are reported in Table 3 (meta-
analysis articles) and in Supplementary Table S3. The mean duration of interventions was 12 weeks and the 
median was 10  weeks. Interventions were three  weeks66, six  weeks50,51,68,69, seven  weeks71, eight  weeks54,56,61 
twelve  weeks39,72–75, sixteen  weeks53, eighteen  weeks65, 36  weeks55 and 12  months62. HIEG participants trained 
with a mean frequency of 2.8 times/week, so most of the interventions programs were delivered 3 times/
Table 1.  Risk of bias using PEDro scale. Y: Yes, the item was satisfied in the experimental protocol; N: No, 
the item was not satisfied in the experimental protocol Items: (1) Eligibility criteria; (2) Random allocation; 
(3) Concealed allocation; (4) Similarity of the groups at baseline; (4, 7–11) Key outcomes; (5–7) Blinding 
process; (8) Final measure with 85% of the initial sample size; (9) intent-to-treat analysis; (10) Between-group 
comparisons report; (11) Point and variability measures.
Validity External item Internal items
Statistic 
items
Total scoreStudy 1 2 3 4 5 6 7 8 9 10 11
Pereira et al. (2020) Y Y Y Y N N N Y N Y Y 6
Mijwel et al. (2018) Y Y Y Y N N N Y Y Y Y 7
Christensen et al. (2018) Y Y N Y N N N Y Y Y N 5
Adams et al. (2018) Y Y Y Y N N Y Y Y Y Y 8
Persoon et al. (2017) Y Y Y Y N N Y Y Y Y Y 8
Brunet et al. (2017) Y N N N N N N Y N Y Y 3
Van Waart et al. (2017) Y Y Y Y N N N Y N Y Y 6
Dunne et al. (2016) Y Y Y Y N Y Y Y N Y Y 8
Toohey et al. (2016) Y Y N Y N N N Y N Y Y 5
Waked,et al. (2016) Y Y Y Y N N N Y N Y Y 6
Schmitt et al. (2016) Y Y Y Y N N N Y N Y Y 6
Edvardsen et al. (2015) Y Y Y Y N N N Y Y Y Y 7
Martin et al. (2015) Y Y Y Y Y N N Y N Y Y 7
Moller et al. (2015) Y Y Y Y N N Y N N Y Y 6
Kampshoff et al. (2015) Y Y Y Y N N Y N Y Y Y 7
Van Wart et al. (2015) Y Y N Y N N N Y Y Y Y 6
Midtgaard et al. (2013) Y Y Y Y N N N N Y Y Y 6
Andersen et al. (2013) Y Y Y Y N N N N Y Y Y 6
Cormie et al. (2013) Y Y Y Y N N N Y Y Y Y 7
Hwang et al. (2012) Y Y Y Y N N Y N N Y Y 6
Adamsen et al. (2009) Y Y Y Y N N N Y Y Y Y 7
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Study Design Group
Sample size (% of 
females) Age (SD) Cancer type (%) Treatment Timing BMI
Egegaard et al. (2019) Feasibility Study
CG n = 7 (71.4%) 65 (4.7) Non-smallcell lung 
Cancer (NSCLC) Chemoradiotherapy
During 24.2 (1.9)
HIEG n = 8 (62.5%) 64 (5.8) During 24.1 (4.4)
Mijwel et al. (2018) Randomized Clinical Trial
CG n = 60 (100%) 52.6 (10.2)
Breast cancer Chemotherapy During
NR
HIEG-R n = 74 (100%) 52.7 (10.3) NR
HIEG-A n = 72 (100%) 54.4 (10.3) NR
Adams et al. (2018) Phase 2 Randomized Controlled Trial













Van Waart et al. 
(2017) Pilot trial

















Persoon et al. (2017) Randomized con-trolled trial










Toohey et al. (2016) Pilot study
HIEG n = 8 (100%) 47.25(13.49)
Colon (6.25%) Cervi-
cal (6.25%) Melanoma 
(6.25%) Ovarian 
(12.5%) Breast 
(56.25%) Breast and 












tion + endocrine 
(50%)
After NR
MIEG n = 8 (100%) 55.88 (11.81) After NR
Schmitt et al. (2016) Single arm, non- randomized
HIEG n = 13 (100%) 53 (8)










LIEG n = 13 (100%) 54 (9)










Dunne et al. (2016) Randomized clinical trial
CG n = 17 (23.5%) 62
Colorectal liver 
metastasis
Chemotherapy (60%) Before 29.7 (4.2)





CG n = 92 (78%) 54 (10.9)
Breast (63%) Colon 
(17%)
Ovarian (6%) Lym-




Surgery + radiation 
(51%) Immunother-
apy (20%) Homonal 
therapy (47%)
After NR
HIEG n = 91 (80%) 54 (11.0)
Breast (68%) Colon 





Surgery + radiation 
(45%) Immunother-
apy (18%) Homonal 
therapy (50%)
After NR
LMIEG n = 95 (82%) 53 (11.3)
Breast (65%) Colon 
(20%)
Ovarian (3%) Lym-
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Study Design Group
Sample size (% of 
females) Age (SD) Cancer type (%) Treatment Timing BMI
Martin et al. (2015) c) Randomised con-trolled trial



















Martin et al. (2015) a) Randomised con-trolled trial























CG n = 77 (100%) 51.6 (8.8)
Breast cancer
Surgery (78%) Radia-
tion (78%) During NR
HIEG n = 76(97%) 49.9 (8.4) Surgery (74%) Radia-tion (79%) During NR
LIEG-H n = 77(100%) 50.5 (10.1) Surgery (81%) Radia-tion (78%) During NR
Møller et al. (2015) Randomised feasibil-ity study
CG n = 16 (12.5%) 46.95 (9.19) Colon and breast cancer Chemotherapy During 25.54 (4.9)
HIEG n = 15 (7.14%) 57.17 (10.51) Colon and breast cancer Chemotherapy During 24.39 (5.27)










After surgey 25.1 (5.2)




After surgey 25.4 (5.1)
Cormie et al. (2013) Randomised con-trolled trial
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week37,50,51,54,55,60–63,68,69,75,76, although in some were 2 days/week39,53,57,58,65,67,70 and 5 days/week71. All high-inten-
sity interventions were supervised and conducted indoors, except Schmitt et al. (2016), who evaluated the effects 
of a program performed outside on a paved uphill  road66. Mean duration was 62.5 min but included sessions 
of 20  min71,75, 20 to 30  min74, 30 to 40  min61,72, 40  min50, 50  min57,58, 60  min39,53,54,60,65, 70  min55, 75  min66,70 and 
90  min51,56,68,69.
All HIT components included a cardiovascular exercise component, except Cormie et al. (2013), which 
included resistance training  only39. In some interventions, HIT was conducted in interval bouts of 30  s65,71,73, 
1   min66 3   min53, 4   min63, 5 to 8   min61. Others incorporated HIT utilizing continuous aerobic training 
 protocols51,54,57,68,69. Across the studies, there were a variety of methodologies used to set high intensity depending 
on  VO2: 95%  VO2 max.63, > 90%  VO2 peak, 80%  VO2peak61, 80%  VO2max54; based on heart rate: > 85%  HRmax75, 
95%  HRpeak51,60,66,68,69; based on power: 95% Wpeak  power71; based on Borg’s Rating of perceived exertion 
scale: 18 of the Borg’s Rating of perceived exertion  scale53; and based on the maximum short exercise capacity 
(MSEC)65,67, 80% of predicted maximal  workload57,58. Of equal importance, the prescribed rest during HIT 
varied from 30  s71 to 1  min53,73,75, 2  min66, or 3 min of active  recovery63. Most of the interventions supplemented 
the HIT component either with resistance  training51,53,54,57,58,60,62,65,68–70,73 Other studies complemented HIT with 
low-intensity sessions like body awareness, relaxation, or  massage51,68,69. Data regarding participants’ adherence 
are presented in Table 3 and Supplementary data (Table S3). The mean percentage rate of sessions completed for 
participants in each group was HIEG 76.7%; LMEG 72.9%; aerobic exercise 82.3%; and resistance exercise 74.0%.
Study Design Group
Sample size (% of 
females) Age (SD) Cancer type (%) Treatment Timing BMI
Andersen et al. (2013) Randomised con-trolled trial
CG n = 107 (72%) 47.8 (10.4)
Breast (47.66%) 
Bowel (14.02%) Ova-
ries (8.41%) Testicles 
(6.54%) Oesophagus 
(0.93%) Brain (1.87%) 
Cervix (1.87%) Phar-






HIEG n = 106 (79.2%) 47.1 (10.8)
Breast (49.05%) 
Bowel (13.21%) Ova-










Hwang et al. (2012) Randomised con-trolled trial













Adamsen et al. (2009) Randomized controltrial
CG n = 134 (70.9%) 47.2 (10.6)
Breast (44.03%) 
Bowel (12.68%) Ova-
ries (8.2%) Testicular 
(6.7%) Oesophagus 
(2.23%) Brain (2.98%) 
Cervix (1.5%) Phar-



















Table 2.  Baseline characteristics of the participants included in the meta-analysis. CG: control group, HIEG: 
high-intensity exercise group, HIEG-R: high-intensity resistance exercise group, HIEG-E: high-intensity 




Scientific Reports |        (2021) 11:15089  | https://doi.org/10.1038/s41598-021-94476-y
www.nature.com/scientificreports/






CG 7 weeks Daily life Activity tracker (Garmin®vívosmart®)
HIEG 7 weeks 20 min 5 times per week
5 min warm-up
HIIT: 1st and 3rd 
cycle ergometer 
intervals: 5 × 30 s with 







1st,  3rd interval 
80–95% (W Peak 
Power)










College of Sports 
Medicine exercise 
recommendations
HIEG-R 16 weeks 60 min 2 times/week Exercise clinic
5 min aerobic 
warm-up
HIIT cycle exercise: 
















HIEG-A 16 weeks 60 min 2 times/week Exercise clinic
5 min aerobic 
warm-up
HIIT cycle exercise: 
3 × 3 min intervals 
with 1 min recovery
Aerobic: 20 min of 
cycle ergometer, 
elliptical ergometer, 




HIIT: intervals at 
16–18 RPE





HIEG 12 weeks 35 min 3 times/week Supervised
5 min warm-up and 
cool-down
HIIT:4 × 4 min inter-
vals with 3 min active 
recovery
Warm-up: at ± 5% 
of the ventilatory 
threshold
Intervals: from 75 
to 95% VO2máx
Recovery: 5%-10% 




Van Waart et al. 
(2017)
CG Moderate intensity leisure-time sports
HIEG
From the first cycle 
of chemotherapy to 
3 weeks
after the last cycle
50 min 2 times/week Supervised
Resistance: 20 min 6 
large muscle groups 2 
series of 8 repetitions
Cardiovascular 
MHIT: 30 min
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ance: 6 standardized 
exercise muscles. 
Week 1–12: 2 series of 
10 repetitions
HIIT: 2 series of8 min 
cycling
Week 1–8 30 s blocks 
with 60 s blocks





blocks at 65% 
(maximal short 
exercise capacity)




every 4 weeks by 
a performing of 
the indirect 1-RM 
measurements and 





HIEG 12 weeks 20 min 3 times/week Supervised
5 min warm-up
HIIT: 7 × 30 s inter-
vals with 1 min rest
5 min cool-down
Intervals ≥ 85% 
(HRmax)
From 3 intervals 
in the first session 
to 7 intervals in 
week 5
Additional control: 









 ≤ 55% predicted 
maximal heart rate NR
Schmitt et al. 
(2016)









Intervals: > 95% 
(HRpeak)
93% partipants all 
sessions
LMIEG 3 weeks 75 min 6 sessions
Outside (paved 















HIIT: Intervals of 
high and moderate 
intensity
High inten-
sity > 90% (VO2 
peak)
Moderate 
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Table 3.  Description of the high-intensity exercise interventions included in the meta-analysis. CG: control 
group, HIEG: high-intensity exercise group, LIEG: low-intensity exercise group, LMIEG: low to moderate 
exercise group, HIT: high-intensity training, HIIT: high-intensity interval training, MHIT: moderate to high 
intensity training, METs: Metabolic equivalent of task, RM: maximum repetition, HR: heart rate,RPE: the 
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Health‑related quality of life outcomes. According to the EORTC QLQ-C30 scoring manual, the 
results, including SF-36 and FACT-G questionnaires, were divided into three categories shown in Table 4: Global 
health status, Functional scales, and Symptom  scales77. Below are the results of the exercise programmes charac-
teristics showing the interventions needed to achieve higher HRQoL benefits. Tthe supplementary data included 
explain the description of each HRQoL dimension results with their corresponding figure resume (from Fig-
ure S1 to Figure S10), and all the meta-analyses performed are reported in the supplementary data (from Sup-
plementary Figure S11 to Supplementary Figure S61).
Physical exercise and treatment timing. When the HIEG exercise programs were implemented during cancer 
treatments, physical functioning (p = 0.0005, with SMD of 0.42 and a 95% CI from 0.18 to 0.66) role function-
ing (p = 0.0003, with SMD of 0.35 and a 95% CI from 0.16 to 0.54) and social functioning (p = 0.03, with SMD 
of 0.12 and a 95% CI from 0.01 to 0.23) seemed to improve more than the CG. In contrast, those variables were 
not significantly improved from after-treatment interventions. Moreover, outcomes of global health dimensions 
showed similar between-group differences in exercise programs conducted during (p = 0.02, with SMD of 0.22 
and a 95% CI from 0.03 to 0.40) and after (p = 0.003, with SMD of 0.30 and a 95% CI from 0.10 to 0.50) cancer 
treatments.
Intervention length. Results showed higher between-group differences (HIEG vs CG) when performing HIT 
in exercise programs of ≤ 8 weeks duration, including physical function (p = 0.04, with SMD of 0.04 and a 95% 
CI from 0.01 to 0.45) and role functioning (p = 0.02, with SMD of 0.26 and a 95% CI from 0.04 to 0.49). For 
HIT programs lasting more than 8 weeks there was no significant between-group differences (physical func-
tion p = 0.05, role functioning p = 0.07). However, cognitive functioning reached higher significant differences 
between the CG and the EG in interventions longer than 8 weeks (p = 0.04, with SMD of 0.20 and a 95% CI 
from 0.01 to 0.40). All HIT durations showed significant differences between CG and HIEG in the global health 
dimensions (≤ 8 weeks: p = 0.04; > 8 weeks: p = 0.002) and fatigue (≤ 8 weeks: p = 0.008; > 8 weeks: p = 0.001).
Table 4.  Sum of HRQoL results obtained and the corresponding questionnaires used. : Significant 
differences between the control group and the high-intensity exercise group. No comparison between the 
high-intensity exercise group and the low-moderate group was significant. QLQ-C 30: European Organisation 
for Research and Treatment of Cancer quality of life Questionnaire, SF-36: Short-form 36, FACT-G: Functional 
Assessment of Cancer Therapy (General).





During and after          HIT+ resistance training  
≤8 weeks or >8 weeks          2 or 3 times/week       






During          HIT+ resistance training  
≤8 weeks            2 times/week







During              ≤8 weeks          3 times/week





wellbeing and mental 
health






>8 weeks          2 times/week













≤8 weeks and >8 weeks        2 or 3 times/week
< 120 min and ≥ 120min/week          ≤15 min or >15 min of HIT
QLQ-C30 (Fatigue)
SF-36 (Vitality)
Body pain No subgroup analysis was significative QLQ-C30 (Pain)SF-36 (Body pain)
Dyspnoea
Not enough data for a subgroup analysis
QLQ-C30 (Dyspnoea)
Diarrhoea QLQ-C30  (Diarrhoea)
Nausea and vomiting QLQ-C30 ( Nuasea and vomiting)
Insomnia QLQ-C30  (Insomnia)
Constipation QLQ-C30  (Constipation)
Appetite loss QLQ-C30  (Appetite loss)
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Exercising frequency. The physical (p = 0.005, with SMD of 0.37 and a 95%CI from 0.11 to 0.62) and cogni-
tive functioning (p = 0.003, with SMD of 0.25 and a 95% CI from 0.08 to 0.42) dimensions showed significant 
between-group differences with higher improvements in HIEG vs CG in interventions conducted 2 times/week. 
In comparison, 3 times/week programs did not show significant between-group differences (physical p = 0.09; 
cognitive p = 0.18). However, patients in the HIEG scored higher than the CG in role functioning with a fre-
quency of 3 times/week (p = 0.04, with SMD of 0.21 and a 95% CI from 0.01 to 0.42), while no significant results 
were observed in interventions with lower frequency (p = 0.05). All of the reported exercise frequencies showed 
significant differences between CG and HIEG in global health (2 times/week: p = 0.002; 3 times/week: p = 0.03) 
and fatigue (2 times/week: p = 0.005; 3 times/week: p = 0.001) dimensions.
Minutes of exercise per week. Results showed significant improvements in HIEG compared to CG in global 
health (p = 0.03, with SMD of 0.18 and a 95% CI from 0.02, to 0.42) and physical functioning (p = 0.006, with 
SMD of 0.24 and a 95% CI from 0.07 to 0.40) only when patients exercised at least 120 min/week. The fatigue 
dimension was significantly improved in both shorter (< 120 weekly minutes: [p = 0.01]) and longer bouts per 
week (≥ 120 weekly minutes [p = 0.0005]).
Type of exercise programme. Interventions that combined resistance training and HIT showed better improve-
ments compared to the CG in global health (p = 0.0008, with an SMD of 0.25 and a 95% CI from 0.10 to 0.39) 
and physical functioning (p = 0.0006, with an SMD of 0.34 and a 95% CI from 0. 15 to 0.53). Whereas pro-
grams involving only cardiovascular/aerobic HIT achieved significant between-group differences in emotional 
(p = 0.007, with SMD of 0.36 and a 95% CI from 0.10 to 0.63) and social functioning (p = 0.03, with SMD of 0.29 
and a 95% CI from 0.03 to 0.55).
High‑intensity training part duration. Patients who participated in programs with components of HIT total-
ling ≤ 15 min increased their physical (p = 0.003, with an SMD of 0.29 and a 95% CI from 0.10 to 0.48) and role 
function (p = 0.0004, with an SMD of 0.34 and a 95% CI from 0.15 to 0.54) in contrast to the CG. However, in 
HIT lasting longer than 15 min, no significant between-group differences were seen in those variables (p = 0.05 
and p = 0.27, respectively). Moreover, when the HIT portion lasted more than 15 min, global health (p = 0.001, 
with an SMD of 0.32 and a 95% CI from 0.13 to 0.51) and social functioning (p = 0.03, with an SMD of 0.17 
and a 95% CI from 0.01 to 0.33) seemed to improve more in the HIEG than in the CG. For cognitive (≤ 15 min: 
p = 0.04; > 15 min: p = 0.02) and fatigue (≤ 15 min: p = 0.0005; > 15 min: p = 0.01) improvements, both longer and 
shorter HIT durations showed significant between-group differences.
Furthermore, HIEG reported significant improvements compared to a CG in the overall comparison of bodily 
pain, dyspnea and insomnia (p = 0.02, with an SMD of − 0.18 and a 95% CI from − 0.21 to − 0.02 in pain analysis; 
p = 0.002 with an SMD of − 0.34 and a 95% CI from − 0.55 to − 0.13 in the dyspnoea results and p = 0.003, with 
an SMD of − 0.29 and a 95% CI from − 0.47 to − 0.10 in insomnia). There were no significant between-group 
differences in diarrhea, nausea, constipation, and appetite loss dimensions.
The meta-analysis did not include the global calculation of HRQoL because of the data heterogeneity from 
the different questionnaires’ measures, despite this there were significant improvements in most of the articles 
 analyzed54–56,59,62,69,74,75 as the Supplementary Tables S4 and S5 report.
Discussion
This study aimed to explore the effect HIT on HRQoL dimensions in cancer patients and survivors. We also aimed 
to evaluate the optimal characteristics of HIT for dimensions of HRQoL with respect to intervention timing 
and cancer treatment, mode of exercise, and exercise dose. We found that HIT improves global quality of life, 
physical functioning, role functioning, social functioning, cognitive functioning, fatigue, pain, dyspnoea, and 
insomnia, compared to an inactive control group. The inclusion of resistance training seemed critical to improve-
ments in global health and physical functioning. No significant differences were found when the effects of HIT 
were compared to low to moderate-intensity exercise. Improvements in HRQoL were observed during cancer 
treatment when training occured for more than eight weeks, with a frequency of 2 days/week, and a volume of 
at least 120 min/week with the HIT component duration in each session of at least 15 min.
Global health and physical function were the most commonly reported variables studied in exercise and 
cancer reviews, and findings here suggest that HIT consistently shows improvements in these outcomes com-
pared to an inactive control  group32,33. Data support positive global health changes with intense  exercise37, but 
are contrary to Mugele et al. (2019), who focused solely on High Intensity Interval Training (HIIT) in their sys-
tematic  review38. The broader definition of HIT might explain the data we observed here, but it is clear further 
studies are required to understand the role of HIT, including HIIT, specifically on HRQoL outcomes in cancer.
The subgroup analysis made regarding an intervention’s timing showed statistically positive effects in the 
global health dimension, physical functioning, role functioning, and social functioning during cancer treatments. 
Only the global health dimension showed a positive increase in after-treatment HIT. In line with our findings, 
the functional variables of HRQoL decrease progressively across  chemotherapy78. Our data suggest that this 
decline might be moderated with HIT, particularly regarding depression and anxiety,  function79 and activities 
of daily  living80. Most of the negative side effects of cancer and its treatments are related to reduced physical 
functioning, reduced mobility due to surgery or  chemotherapy81,  lymphedema82, negative body composition 
changes as  sarcopenia83, or  osteoporosis84. Providing opportunities to mitigate these deleterious effects through 
HIT is highly important since more than half of all cancer patients develop a mobility disability because of the 
disease and its treatments’ adverse side-effects85.
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Exercise interventions can and should be an important therapeutic modality prior to the onset of medi-
cal  treatment86. Exercise has been shown to increase baseline physical functioning, reduce treatment-related 
 impediments30, and help a patient maintain overall strength during  treatment87. Post-treatment exercise can help 
the patient return to baseline and reduce subsequent side-effects88. The meta-analysis underlined the important 
role of resistance training in improving global health and physical function. Incorporating strength training 
in HIT programs is likely to increase muscle function, reduce the risk of sarcopenia, and reduce the risk of 
 mortality89 and treatment  toxicity90. This has been shown independent of age, cancer stage, or  BMI91, and is partly 
explained through an anti-inflammatory  response92. Further, resistance training may regulate deficiencies in 
skeletal muscle and adipose tissue known as  cachexia93,94. However, it should be noted that interventions which 
included resistance training had lower adherence rates compared to aerobic exercise, which has been reported 
in other chronic disease  patients95. Poor adherence might also explain why social and emotional functioning 
only significantly increased in the aerobic component programs, not in the resistance exercise modalities. To 
improve adherence, researchers and exercise specialists might wish to adopt a co-production approach, seeking 
to co-create the specific training strategies with people who have a cancer diagnosis, taking into account what 
matters most to  them95.
Cancer and its associated treatments can cause severe side-effects during drug therapy, with pain and fatigue 
the most  common96. Fatigue-related to cancer is reported by 70% of cancer  patients97. The complaint of cancer-
related fatigue is associated with immune response dysregulation, inflammation, metabolic and mitochondrial 
function impairment, neuroendocrine function impairment, and genetic  biomarkers98; however, with exercise, 
these parameters can be  improved99. To decrease fatigue, HIT, as well as other exercise modes, seems to be 
 effective30, possibly more so than pharmacological or psychological  therapies100. Other symptoms like pain, 
insomnia, and dyspnea also appear to improve via  exercise35and without aggravating cancer symptoms, although 
this requires further  investigation101.
Interventions lasting more than 8 weeks reported greater increases in HRQoL compared to shorter duration 
programs, which is consistent with a previous review of HIT  interventions37. Greater improvements across a 
range of cancer-related outcomes were observed with exercising 3 times/week compared to training 2 times/week, 
except for role functioning (3 times/week). The American College of Sports Medicine recommends exercising 
two to three times/week101, which agrees with the findings of our study and a previous meta-analysis37. Three 
exercise sessions per week will also make it easier for individual cancer patients to achieve 120 min of weekly 
exercise, which seems to be important for increasing HRQoL, particularly when each session includes at 15 min 
of HIT. Some programs have included family members with hospitalized  patients102.
This article presents valuable information about the role of high-intensity exercise as part of treatment and 
recovery in cancer, specifically in terms of HRQoL. The data from the systematic review and meta-analysis 
should be viewed in the light of the following limitations. Only articles written in English or Spanish were 
included, so not all the available information was analyzed. The intervention description, as well as the sub-
group meta-analysis, was undertaken with the published available details. Where a study had incomplete data 
(e.g. sessions’ duration, HIT minutes, after intervention mean and standard deviation, etc.), data were omitted 
to the corresponding subgroup calculation. For the meta-analysis procedure, data from at least three articles 
were needed to make a subgroup analysis. Thus, assessments concerning the cancer type and all the subgroups 
analysis considering each intervention characteristic were not possible. Therefore, more information could be 
added with further studies. It must be considered that three of the included articles combined HIT with body 
awareness, relaxation, or massage interventions, each of which could influence HRQoL.
Conclusion
This is the first meta-analysis exploring the effects of HIT on the HRQoL of cancer patients and survivors. Data 
from this systematic review and meta-analysis suggests that HIT as part of exercise therapy for people with a 
cancer diagnosis can improve global health and provide physical, cognitive, and social functioning benefits 
compared to controls. In addition, fatigue, bodily pain, dyspnea, and insomnia decreases can be achieved with 
HIT, all with similar outcomes observed using low-moderate intensity exercise. Dimensions of HRQoL showed 
the largest positive effects when the programs were delivered as part of cancer treatment and included resist-
ance training. Ultimately, exercise programs may need to be longer than 8 weeks, with a HIT frequency of 2 
times/week, and a total duration of at least 120 min/week, including a HIT component of more at least 15 min, 
to achieve the highest return in HRQoL. However, as it is the first meta-analysis about the effects of HIT in the 
HRQoL of cancer patients and survivors, further research is required to support our findings.
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